Expression of Spermidine/Spermine N1-Acetyl Transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

Prostate

Volumn 75, Issue 11, 2015, Pages 1150-1159

  Huang, Wei ^a   Eickhoff, Jens C ^a   Mehraein Ghomi, Farideh ^a   Church, Dawn R ^a   Wilding, George ^a   Basu, Hirak S ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

biomarker for progression; cancer prognosis; oxidative Stress; SSAT

Indexed keywords

ACYLTRANSFERASE; ENZYME ANTIBODY; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; RNA; SPERMIDINE SPERMINE N' ACETYL TRANSFERASE; SPERMIDINE SPERMINE N' ACETYL TRANSFERASE ANTIBODY; UNCLASSIFIED DRUG; ANDROGEN; DIAMINE N-ACETYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOGISTIC REGRESSION ANALYSIS; MALE; METASTASIS; METASTASIS POTENTIAL; OXIDATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TISSUE LEVEL; TISSUE MICROARRAY; VERY ELDERLY; CANCER GRADING; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS;

ACETYLTRANSFERASES; AGED; AGED, 80 AND OVER; ANDROGENS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

EID: 84932194289     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22996     Document Type: Article

References (38)

1. Concato J,. Probability, uncertainty, and prostate cancer. Ann Intern Med 2013; 158 (3): 211-212.
2. Gleason D F,. The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In:, Tannenbaum M, editor. Urologic pathology: The prostate. Philadelphia, PA: Lea and Febiger; 1977. pp. 171-198.
3. Mani RS, Chinnaiyan AM,. Triggers for genomic rearrangements: Insights into genomic. Nat Rev Genet 2010; 11 (12): 819-829.
4. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD,. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89 (1): 123-134.
5. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK,. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68 (6): 1777-1785.
6. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL,. The role of oxidative stress in prostate cancer. Eur J Cancer Prev 2012; 21 (2): 155-162.
7. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW,. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 2006; 66 (19): 9519-9526.
8. Chaiswing L, Zhong W, Oberley TD,. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med 2014; 67: 342-352.
9. Oberley TD, Zhong W, Szweda LI, Oberley LW,. Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate 2000; 44 (2): 144-155.
10. Tam NN, Nyska A, Maronpot RR, Kissling G, Lomnitski L, Suttie A, Bakshi S, Bergman M, Grossman S, Ho SM,. Differential attenuation of oxidative/nitrosative injuries in early prostatic neoplastic lesions in TRAMP mice by dietary antioxidants. Prostate 2006; 66 (1): 57-69.
11. Tsirmoula S, Dimas K, Hatziapostolou M, Lamprou M, Ravazoula P, Papadimitriou E,. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo. Cancer Sci 2012; 103 (10): 1826-1832.
12. Polytarchou C, Hatziapostolou M, Poimenidi E, Mikelis C, Papadopoulou A, Parthymou A, Papadimitriou E,. Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta. Int J Cancer 2009; 124 (8): 1785-1793.
13. Hatziapostolou M, Polytarchou C, Katsoris P, Courty J, Papadimitriou E,. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J Biol Chem 2006; 281 (43): 32217-32226.
14. Polytarchou C, Hatziapostolou M, Papadimitriou E,. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J Biol Chem 2005; 280 (49): 40428-40435.
15. Hatziapostolou M, Delbe J, Katsoris P, Polytarchou C, Courty J, Papadimitriou E,. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 2005; 65 (2): 151-158.
16. Papadimitriou E, Polykratis A, Hatziapostolou M, Parthymou A, Polytarchou C, Mikelis C,. Heparin affin regulatory peptide: A new target for tumour therapy? Curr Cancer Drug Targets 2004; 4 (6): 471-482.
17. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA,. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013; 34 (3): 503-512.
18. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G,. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 2005; 63 (2): 155-168.
19. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G,. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Prostate 2008; 68: 924-934.
20. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G,. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res 2010; 70 (11): 4560-4568.
21. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G,. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2009; 69 (19): 7689-7695.
22. Cohen SS., A guide to the polyamines. Oxford: Oxford University Press; 1998. pp. 296-319.
23. Seiler N,. Polyamine metabolism. Digestion 1990; 46 (Suppl 2): 319-330.
24. Hölttä E., Oxidation of spermidine and spermine in rat liver: Purification and properties of polyamine oxidase. Biochemistry 1977; 16 (11): 91-100.
25. Wang Y, Hacker A, Murray-Stewart T, Frydman B, Valasinas A, Fraser AV, Woster PM, Casero RA Jr., Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): Potential role in determining drug sensitivity. Cancer Chemother Pharmacol 2005; 56 (1): 83-90.
26. Babbar N, Murray-Stewart T, Casero RA Jr., Inflammation and polyamine catabolism: The good, the bad and the ugly. Biochem Soc Trans 2007; 35 (Pt 2): 300-304.
27. Schisterman EF, Perkins NJ, et al., Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 2005; 16: 73-81.
28. Singh U, Keirstead N, Wolujczyk A, Odin M, Albassam M, Garrido R,. General principles and methods for routine automated microRNA in situ hybridization and double labeling with immunohistochemistry. Biotech Histochem 2014; 89 (4): 259-266.
29. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W,. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: A tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol 2009; 17 (1): 23-30.
30. Ahmed KM, Li JJ,. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008; 44 (1): 1-13.
31. Baltimore D., NF-kappaB is 25. Nat Immunol 2011; 12 (8): 683-685.
32. Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, Tennstedt P, Schlomm T, Mes-Masson AM, Saad F,. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. Eur J Cancer 2013; 49 (10): 2441-2448.
33. Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F,. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer 2010; 102 (7): 1163-1173.
34. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J,. Prostate cancer and physical activity: Adaptive response to oxidative stress. Free Radic Biol Med 2013; 60: 115-124.
35. Barré B1, Coqueret O, Perkins ND,. Regulation of activity and function of the p52 NF-κB subunit following DNA damage. Cell Cycle 2010; 9 (24): 4795-4804.
36. Nadif R, Mintz M, Jedlicka A, Bertrand JP, Kleeberger SR, Kauffmann F,. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic Res 2005; 39 (12): 1345-1350.
37. Hu J, Feng F, Zhu S, Sun L, Li G, Jiang N, Shang Z, Niu Y,. Catalase C-262T polymorphism and risk of prostate cancer: Evidence from meta-analysis. Gene 2015; 558 (2): 265-270.
38. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M,. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464 (7286): 302-305.